HM7: Paediatric investigational plans

2D4A7824

In her introduction, Sandra Lourenco explained that even though the EU’s paediatric legislation came into effect more than 15 years ago, much medical need persists in the paediatric population. Global development of paediatric medicines can be facilitated by strengthening the international collaboration and alignment of regulatory requirements for PIPs. Therefore, it is important to collectively continue our efforts to develop medicinal products suitable for use in paediatric patients.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!